News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

Project Update: Nanite Looks to Advance Polymer-Based Encapsulation for CMT1A

Feb 9, 2024 | CMT Research Updates, CMTRF Funded Research

CMT 1A results from the duplication of the myelin protein 22 gene (PMP22) in Schwann cells. This causes excessive production of the PMP22 protein which disrupts the myelination process of peripheral nerves and ultimately results in axonal loss and muscle wasting over...

Cisco’s Santo Caivano Joins CMT Research Foundation Board of Directors

Jan 16, 2024 | Press Releases

CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, today announced that Santo Caivano, Director, Customer Engagements of Cisco’s CAP (Critical Accounts Program) Americas team,...

Kayleena Speakman Joins The CMT Research Foundation as Communications Manager

Jan 4, 2024 | News, Press Releases

Kayleena Speakman has joined The CMT Research Foundation, a patient-led, non-profit focused on delivering treatments and cures for CMT as Communications Manager responsible for emails, blogs, social media posts and opinion pieces for the CMT community, donors,...

An Extraordinary Year and the Road Ahead

Jan 3, 2024 | News

As we begin 2024, I want to take a look back and celebrate the extraordinary year we had at the CMT Research Foundation. Since 2018, CMTRF has had an outsized impact on inspiring drug hunters to work on developing therapeutics for CMT and establishing itself as a key...

Dr. Grace Pavlath Joins CMT Research Foundation’s Research Advisory Committee

Nov 14, 2023 | Press Releases

ATLANTA (November 14, 2023) The CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced that Dr. Grace Pavlath has joined its newly formed Research Advisory Committee...

Update from the Novartis CMT1A Development Team

Oct 29, 2023 | About CMT, Drug Development, News

As you know, the CMT Research Foundation is proud to have introduced DTx leadership to Charcot-Marie-Tooth disease in 2019. We funded their first work in CMT to demonstrate the FALCON platform's potential to deliver a drug to the Schwann cells. And from there, the...

ARM-101: A Potential “Precision Drug Therapy” For CMT1A

Oct 24, 2023 | CMTRF Funded Research, Research News

The CMT Research Foundation has invested in a project at Armatus Bio, Inc. that will advance a novel miRNA gene therapy candidate for CMT type 1A. Principal Investigator Dr. Brian Price and his colleagues aim to harness the potential of microRNAs (miRNAs), snippets of...

CMT Research Foundation Invests in Armatus Bio, Inc. to Advance Potential Therapeutic for CMT1A

Oct 23, 2023 | CMT Research Updates, CMTRF Funded Research

ATLANTA (October 24, 2023) The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has invested in a project at Armatus Bio that will advance a novel miRNA gene therapy candidate for CMT type...

CMT Research Foundation Launches Research Advisory Committee of Renowned Scientific Experts

Oct 18, 2023 | Press Releases, Research News

ATLANTA (October 18, 2023) The CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced the formation of a Research Advisory Committee (RAC) consisting of: Dr. William...

Arthur Suckow, former Co-founder and Chief Executive Officer of DTx Pharma, Joins CMT Research Foundation Board of Directors

Oct 3, 2023 | News, Press Releases

ATLANTA (October 3, 2023) CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced that Arthur Suckow, Ph.D. former Co-founder and Chief Executive Officer of DTx...